Accéder au contenu
Merck

Emergence of Candida auris in Brazil in a COVID-19 Intensive Care Unit.

Journal of fungi (Basel, Switzerland) (2021-04-04)
João N de Almeida, Elaine C Francisco, Ferry Hagen, Igor B Brandão, Felicidade M Pereira, Pedro H Presta Dias, Magda M de Miranda Costa, Regiane T de Souza Jordão, Theun de Groot, Arnaldo L Colombo
RÉSUMÉ

In December 2020, Candida auris emerged in Brazil in the city of Salvador. The first two C. auris colonized patients were in the same COVID-19 intensive care unit. Antifungal susceptibility testing showed low minimal inhibitory concentrations of 1 µg/mL, 2 µg/mL, 0.03 µg/L, and 0.06 µg/mL for amphotericin B, fluconazole, voriconazole, and anidulafungin, respectively. Microsatellite typing revealed that the strains are clonal and belong to the South Asian clade C. auris. The travel restrictions during the COVID-19 pandemic and the absence of travel history among the colonized patients lead to the hypothesis that this species was introduced several months before the recognition of the first case and/or emerged locally in the coastline Salvador area.

MATÉRIAUX
Référence du produit
Marque
Description du produit

Sigma-Aldrich
Anidulafungin, ≥97% (HPLC)